Provided is a method of producing mineral function water showing beneficial effects, such as antioxidant effects, or the like. The water including contains mineral-containing water (A) and mineral-containing water (B) according to a ratio of 1:5 to 1:20 (weight ratio), the mineral-containing water (A) containing first mineral components eluted from mineral-imparting material (A) containing: vegetation raw material, woody plant raw material, and sulfur raw material, the mineral-containing water (B) containing second mineral-containing water (B) containing the mineral component eluted from inorganic mineral-imparting material (B).

The present invention relates to a synbiotic composition comprising a probiotic bacterial strain and a prebiotic growth medium which is specific to the growth of the probiotic bacterial strain, wherein the bacterial strain is capable of producing the same growth medium by reverse enzyme reaction. The present invention also relates to methods of producing and screening for such compositions.

A manufacturing method of an ascorbic acid dispersion material includes a heating step of adding an ascorbic acid into a solvent including one or more selected from the group consisting of glycerin, diglycerin, polyglycerin represented by a following formula, and propylene glycol, and heating the ascorbic acid to a predetermined temperature to dissolve the ascorbic acid; a cooling step of cooling a solution with the ascorbic acid dissolved therein at a cooling rate of 5 to 20 C./min until a temperature of the solution reaches 35 to 50 C. to remove heat from the solution; and a growth step of storing the solution after completion of the cooling step at 27 to 38 C. for a predetermined period to promote crystal growth so that the ascorbic acid crystal has a flat plate shape, a thickness of 0.05 to 3 m, and an average particle diameter of 50 to 100 m.

##STR00001##

A pharmaceutically acceptable oral dosage form for delivery of an agent to an intestinal site has one or more active agent regions having an active agent to be delivered to the intestinal site, one or more drying agent regions having at least one drying agent therein capable of drying an area about the intestinal site, the one or more drying agent regions being separate from the one or more active agent regions, and a protective coating at least partially covering a surface of the form. The dosage form has a fluid uptake capacity as measured for the entire dosage form when immersed in a fluid media according to a Dosage Form Fluid Uptake Assay of at least about 20 g fluid per dosage form.

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates

The present invention discloses a thermosensitive nanocapsule and a preparing method thereof. The thermosensitive nanocapsule includes core materials and wall materials. The preparing method includes: first, making water phase and oil phase respectively, forming microemulsion by means of high speed shearing after mixing, and forming nanoemulsion via ultrasonic treatment or high pressure homogenization; then adding nitrogen to the emulsion and carrying out the reaction under a temperature of 40-80 C. for 3-4 hrs in the nitrogen atmosphere; finally obtaining the thermosensitive nanocapsule with an embedding rate of 90-94%, a particle size of less than 150 nm and a dimension polydispersity index of 0.09-0.17. In present invention, the monomer that forms the wall material of the nanocapsules is made from common biological materials, and has a good biocompatibility. The wall material has a temperature sensitivity, and can control the delayed release of core material by adjusting temperature.

Disclosed is a method of treatment or prevention of frailty in an elderly patient, particularly having an age of 60 or older. The method provides the concomitant parenteral administration of a combination of an anabolic steroid and a vitamin D compound. A preferred combination comprises nandrolone decanoate and cholecalciferol (vitamin D.sub.3). The invention, in a further preference, provides a booster therapy to support frail elderly that have undergone hospitalization or surgery to retain independence and regain their regular physical and mental activities.

Cysteine compositions comprising less than about 400 g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.

Cysteine compositions comprising less than about 400 g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.

A new modus and a new regimen of administration of divalent iron relates to therapy of hyposideremia, at the same time reducing toxic side effects. New formulations containing divalent iron compounds are adapted to release iron for intrabuccal absorption, preferably by sublingual absorption, that achieve these objects.